OncoResponse completes final close of $22.5M Series A
March 13, 2017
Biotechnology | Houston, TX | Series A
OncoResponse, a drug discovery company that’s developing therapeutic antibodies against immuno-oncology targets, has been valued at $27.5 million with the new funding. The company secured an initial close of the round in October 2015, then raised additional funding in May 2016 and October 2016.